Simple pharmacometric tools for oral anti‐diabetic drug development: competitive landscape for oral non‐insulin therapies in type 2 diabetes
- 8 March 2010
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 31 (2-3) , 162-177
Abstract
The objectives were to develop a translational model that will help select doses for Phase-3 trials based on abbreviated Phase-2 trials and understand the competitive landscape for oral anti-diabetics based on efficacy, tolerability and ability to slow disease progression. Data for eight anti-diabetics with temporal profiles for fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) from 12 publications were digitized. The monotherapy data consisted of FPG and HbA1c profiles that were modeled using a transit compartment model. Evaluation of the competitive landscape utilized HbA1c literature data for 11 drugs. For the safety metric, tolerability issues with anti-diabetic drug classes were tabulated. For disease progression, the coefficient of failure method was used for assessing data from two long-term trials. The transit rate constants were remarkably consistent across 12 trials and represent system-specific/drug-independent parameters. The competitive landscape analysis showed that the primary efficacy metric fell into two groups of ΔHbA1c: >0.8% or ∼0.8%. On the safety endpoints, older agents showed some tolerability issues while the new agents were relatively safe. Among the different drug classes, only the thiazolidinediones appeared to slow disease progression but may also increase heart failure risk. In conclusion, the ability of system-specific parameters to predict HbA1c provides a tool to predict the expected efficacy profile from abbreviated dose-finding trials. To be commercially viable, new drugs should improve ΔHbA1c by about 0.8% or more and possess safety profiles similar to newer anti-diabetic agents. Thus, this study proposes a suite of simple yet powerful tools to guide type-2-diabetes drug development. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 31 references indexed in Scilit:
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004-2006The Journal of Clinical Pharmacology, 2008
- Pharmacokinetic/Pharmacodynamic Modelling in??Diabetes MellitusClinical Pharmacokinetics, 2008
- Influence of Administration Rate on Propofol Plasma–Effect Site EquilibrationAnesthesiology, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 DiabetesDiabetes Care, 2005
- Coefficient of failure: a methodology for examining longitudinal β‐cell function in Type 2 diabetesDiabetic Medicine, 2002
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Repaglinide in Type 2 Diabetes: A 24-Week, Fixed-Dose Efficacy and Safety StudyThe Journal of Clinical Pharmacology, 2000
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998